연구성과로 돌아가기

2024 연구성과별 연구자 정보 (1654 / 2344)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma Yun, Kum-Hee Yun, KH 4
Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma Lee, Young Han Lee, YH 5 AAJ-8828-2020 Park, Young-Jae
Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma Jun, Hyun Jung Jun, HJ 6
Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma Rha, Sun Young Rha, SY 7
Phase IB/II trial of durvalumab plus doxorubicin combination in patients with advanced soft-tissue sarcoma Kim, Hyo Song Kim, HS 8 D-5568-2011 Kim, Hyun
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB Tak, Won Young Tak, WY 1 Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea tom.evans@barinthusbio.com;
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB Chuang, Wan-Lobg Chuang, WL 2 Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan C-9536-2009 Chuang, Wan-Long 0000-0002-2376-421X Chuang, Wan-Long tom.evans@barinthusbio.com;
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB Chen, Chi-Yi Chen, CY 3 Chia Yi Christian Hosp, Chiayi, Taiwan KVZ-1550-2024 Chen, ChiYi tom.evans@barinthusbio.com;
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB Tseng, Kuo-Chih Tseng, KC 4 Dalin Tzu Chi Gen Hosp, Hualien, Taiwan tom.evans@barinthusbio.com;
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB Lim, Young-Suk Lim, YS 5 Univ Ulsan, Coll Med, Coll Med, Seoul, South Korea AFQ-5165-2022 Lim, Young-Suk 0000-0002-1544-577X Lim, Young-Suk tom.evans@barinthusbio.com;
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB Lo, Gin-Ho Lo, GH 6 E Da Hosp, Kaohsiung, Taiwan tom.evans@barinthusbio.com;
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB Heo, Jeong Heo, J 7 Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Coll Med, Busan, South Korea MHQ-1390-2025 Heo, Jeong 0000-0003-0961-7851 Heo, Jeong tom.evans@barinthusbio.com;
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB Heo, Jeong Heo, J 7 Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea MHQ-1390-2025 Heo, Jeong 0000-0003-0961-7851 Heo, Jeong tom.evans@barinthusbio.com;
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB Agarwal, Kaushik Agarwal, K 8 Kings Coll Hosp NHS Fdn Trust, Inst Liver Studies, London, England tom.evans@barinthusbio.com;
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB Bussey, Louise Bussey, L 9 Vaccitech, Harwell, Oxon, South Korea tom.evans@barinthusbio.com;
페이지 이동: